Loading...
Market
Story
Scholar Rock's Apitegromab Succeeds in Phase 3 SMA Trial with p=0.019, Stock Soars 200%
Oct 7, 2024, 12:01 PM
Scholar Rock announced that its drug apitegromab met the primary endpoint in a Phase 3 SAPPHIRE study for treating spinal muscular atrophy (SMA). The trial, which achieved statistical significance with a p-value of 0.019, demonstrated a clinically meaningful improvement in motor function among patients. As a result, Scholar Rock's stock soared more than 200%. The late-stage study involved patients already on standard-of-care treatments such as Spinraza and Risdiplam. The success of the trial positions Scholar Rock as a potential key player in the SMA treatment market.
View original story
Similar markets
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%